The Food and Drug Administration has published information on its website listing the antihypertensive drugs recalled for their combination with carcinogens. Here's what to watch for.

Camber Pharmaceuticals, Inc. has recalled 87 batches of losartan, a medicine for high blood pressure, Thursday after discovering traces of a potential carcinogen.

The recalled 25mg, 50mg, and 100mg tablets contained small amounts of N-methyl 4-amino butyric acid N-Nitroso, or NMBA, according to a company recall notice posted on the website of the Food and Drug Administration. This is the second losartan reminder in a week; Macleods Pharmaceuticals Limited recalled a single batch on February 22nd.

Camber says the drugs have been distributed nationally in retail and mail order pharmacies, in addition to wholesalers and distributors.

"To date, Camber has not received any reports of adverse events related to this recall," the statement said.

The drug is packaged in vials of 30, 90, 500 and 1000. A complete list of the recalled medications is available from the FDA.

The statement said consumers should continue taking the product until their doctor gives them advice.

February 25th: Losartan, medicine for high blood pressure, reminding small amounts of carcinogen

February 13th: A committee of the House wants to know why foreign-made hypertension drugs contain carcinogens

The active ingredient was manufactured by Hetero Labs Limited in India, one of two overseas drug manufacturing plants linked to blood-based drug recalls since last July.

There have been more than a dozen recalls of versions of losartan, valsartan and irbesartan, drugs for the treatment of high blood pressure and heart, containing trace amounts of probable carcinogens. .

The recalled drugs are part of a broad class of medications called angiotensin II receptor blockers, or ARBs, which have the effect of relaxing the blood vessels.

Contribute: Ken Alltucker

Automatic reading

Thumbnails poster

Show captions

Last slide next

Read or share this story: